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-Dystroglycan (DG) has been identiﬁed as the cellular
receptor for lymphocytic choriomeningitis virus
(LCMV) and Lassa fever virus (LFV). This subunit of DG is a
 
highly versatile cell surface molecule that provides a
molecular link between the extracellular matrix (ECM) and
a 
 
 
 
-DG transmembrane component, which interacts with
the actin-based cytoskeleton. In addition, DG exhibits a
complex pattern of interaction with a wide variety of ECM
and cellular proteins. In the present study, we characterized
 
the binding of LCMV to 
 
 
 
-DG and addressed the role of
 
 
 
-DG–associated host-derived proteins in virus infection.
We found that the COOH-terminal region of 
 
 
 
-DG’s ﬁrst
 
globular domain and the NH
 
2
 
-terminal region of the mucin-
 
related structures of 
 
 
 
-DG together form the binding site
for LCMV. The virus–
 
 
 
-DG binding unlike ECM 
 
 
 
-DG
 
 
interactions was not dependent on divalent cations. Despite
such differences in binding, LCMV and laminin-1 use, in
part, an overlapping binding site on 
 
 
 
-DG, and the ability
of an LCMV isolate to compete with laminin-1 for receptor
binding is determined by its binding afﬁnity to 
 
 
 
-DG. This
competition of the virus with ECM molecules for receptor
binding likely explains the recently found correlation
 
between the afﬁnity of LCMV binding to 
 
 
 
-DG, tissue
tropism, and pathological potential. LCMV strains and
 
variants with high binding afﬁnity to 
 
 
 
-DG but not low
 
afﬁnity binders are able to infect CD11c
 
 
 
 dendritic cells,
which express 
 
 
 
-DG at their surface. Infection followed by
dysfunction of these antigen-presenting cells contributes to
immunosuppression and persistent viral infection in vivo.
 
Introduction
 
The interaction of a virus with its cellular receptor is an
important determinant for its host range and tissue tropism.
The recent identification of 
 
 
 
-dystroglycan (DG)* as the
receptor for lymphocytic choriomeningitis virus (LCMV)
and the highly human pathogenic old world arenavirus Lassa
fever virus (LFV) (Cao et al., 1998) opens the possibility to
study the biochemistry of receptor binding and its conse-
quent biological effects. LCMV infection of its natural host,
the mouse, provided novel concepts in immunology and
virology that have been extended to other RNA and DNA
viruses, bacteria, and parasites (Oldstone, 2001; Zinkernagel,
2001). LFV is an important pathogen that causes hemor-
rhagic fevers in humans (Peters et al., 1996), and LCMV is
the prototypic member of the arenavirus family (Southern,
 
1996). Its bisegmented negative strand genome consists of
two single-stranded RNA species: the larger segment en-
codes the virus polymerase (L) and a small zinc finger motif
protein (Z), and the smaller segment encodes the virus
nucleoprotein (NP) and glycoprotein precursor (GP-C).
GP-C is post translationally cleaved into GP1 and GP2. Sev-
eral lines of evidence implicate GP1 in receptor binding
(Kunz et al., 2001).
DG is a highly versatile cell surface receptor that provides
a molecular link between the extracellular matrix (ECM)
and the actin-based cytoskeleton (Ervasti and Campbell,
1991, 1993; Ibraghimov-Beskrovnaya et al., 1992; Henry
and Campbell, 1999; Winder, 2001). Initially encoded as a
single protein, DG undergoes posttranslational cleavage to
form 
 
 
 
-DG, a peripheral protein, and 
 
 
 
-DG, a membrane
protein. DG is expressed in most developing and adult tis-
sues, typically in cell types that adjoin basement membranes
(Durbeej et al., 1998). At those sites, DG plays a critical role
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in cell-mediated assembly of basement membranes (Henry
and Campbell, 1998). 
 
 
 
-DG undergoes high affinity inter-
actions with the ECM proteins laminin-1, laminin-2, agrin,
and perlecan (Ervasti and Campbell, 1991, 1993; Gee et al.,
1994; Talts et al., 1999). Biochemical and structural data
suggest that these interactions engage a lectin-type binding
involving 
 
 
 
-DG–derived carbohydrates (Ervasti and Camp-
bell, 1993; Pall et al., 1996; Yamada et al., 1996; Hohenes-
ter et al., 1999). 
 
 
 
-DG is non covalently associated with the
membrane-spanning 
 
 
 
-DG, which binds to the cytoskeletal
proteins dystrophin and utrophin, and the signal transduc-
tion molecules grb2 and focal adhesion kinase (Henry and
Campbell, 1999). The complex binding pattern of 
 
 
 
-DG
likely results in the formation of tissue-specific 
 
 
 
-DG com-
plexes in the cell membrane. Since specific DG-associated
proteins may enhance or block virus binding, their coexpres-
sion with DG may modulate the susceptibility of a specific
cell for virus infection and represent an important determi-
nant for viral tissue tropism in vivo. Based on their ubiqui-
tous expression, high binding affinity, and large size, ECM
molecules may interfere with virus binding to 
 
 
 
-DG and
therefore provide a barrier for virus infection in vivo.
Clearly, the ability of a virus to displace those ECM proteins
in order to bind its cellular receptor would be determined by
its receptor binding affinity.
Recent studies from our laboratory have documented a
striking and consistent correlation between F260L or F260I
mutations in LCMV-GP1 and the affinity of LCMV bind-
ing to 
 
 
 
-DG, tissue tropism, and pathological potential
(Borrow et al., 1995; Sevilla et al., 2000; Smelt et al., 2001).
LCMV strains and variants with high binding affinity to
 
 
 
-DG replicate preferentially in the white pulp of the spleen
and infect 
 
 
 
-DG
 
 
 
/CD11c
 
 
 
 dendritic cells (DC). Infection
of this important population of antigen-presenting cells re-
sults in a generalized immunosuppression of the host. In
contrast, strains and variants with low binding affinity for
 
 
 
-DG localize primarily to the red pulp of the spleen, show
only very limited infection of CD11c
 
 
 
 DC and do not cause
immunosuppression. Understanding this pivotal linkage be-
tween receptor binding and viral pathogenesis requires de-
tailed molecular analysis of the virus–
 
 
 
-DG interaction.
The present study characterizes LCMV–
 
 
 
-DG binding
biochemically and analyzes the role of 
 
 
 
-DG–associated
host-derived proteins in the virus infection. The results
emphasize that LCMV–
 
 
 
-DG binding is a novel type of
interaction involving globular protein domains and mucin-
related structures of 
 
 
 
-DG. Despite several defined bio-
chemical differences in binding, our data indicate that
LCMV and laminin-1 use overlapping binding sites on 
 
 
 
-DG
and that the ability of a LCMV isolate to compete with
laminin-1 for receptor binding is determined by the virus af-
finity for 
 
 
 
-DG.
 
Results
 
The binding of LCMV is a novel interaction of 
 
 
 
-DG
 
Since previous studies suggest a lectin-type binding for all
 
 
 
-DG–ECM protein interactions described so far, we evalu-
ated to what extent the LCMV–
 
 
 
-DG interaction shares
these biochemical characteristics. To address this question,
virus overlay protein binding assays (VOPBAs) were per-
formed in the presence and absence of divalent cations,
chelating agents, and heparin using 
 
 
 
-DG purified from
skeletal muscle and 
 
 
 
-DG–enriched glycoprotein fractions
isolated from MC57 cells. For comparison, a laminin-1
overlay binding assay was performed. In contrast to 
 
 
 
-DG–
laminin-1 binding and other 
 
 
 
-DG ECM protein interac-
tions, the binding of LCMV to 
 
 
 
-DG was independent of
Figure 1. Biochemical characterization 
of the LCMV– -DG interaction.  -DG 
purified from rabbit skeletal muscle or 
enriched from MC57 cells was subjected 
to VOPBA using 10
7 PFU/ml of LCMV 
clone-13 or to laminin overlay assay 
with 10  g/ml biotinylated laminin-1. 
Bound virus was detected using mono-
clonal antibodies WE33 and WE36 
against LCMV-GP. For detection of 
bound biotinylated laminin-1, HRP-
conjugated streptavidin was used. (A) 
The cation dependence of the binding of 
LCMV and laminin-1 to  -DG was 
tested by addition of 1 mM Ca
2 , 1 mM 
Mg
2 , 10 mM EDTA, or 10 mM EGTA. 
(B) For inhibition with heparin, virus or 
biotinylated laminin-1 were pretreated 
with 0, 25, and 100 mg/ml heparin be-
fore incubation with immobilized  -DG. 
(C) To test for a potential role of  -DG–
derived carbohydrates in virus binding, 
 -DG from MC57 cells was pretreated 
with 0, 1, 10, and 100 mM sodium peri-
odate before the addition of virus. A 
potential role of  -DG–derived terminal 
sialic acids was addressed by neuramini-
dase treatment (D) and competition with 
0, 10, and 100 mM sialic acid (E). 
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divalent cations and insensitive to the chelating agents
EDTA and EGTA (Fig. 1 A). Further, the presence of 
 
 
 
100
 
 
 
g/ml heparin blocked laminin-1 binding completely but
did not significantly affect virus binding (Fig. 1 B). Evi-
dently, this virus–
 
 
 
-DG binding was biochemically distinct
from the interactions between 
 
 
 
-DG and ECM proteins.
Similarly, 
 
 
 
-DG–derived sialic acids were not involved in vi-
rus binding despite their apparent role in 
 
 
 
-DG–laminin
binding (Yamada et al., 1996). Periodate treatment of
 
 
 
-DG, under conditions in which primarily terminal sialic
acid residues but not core glycan structures are oxidized, had
no effect on virus binding (Fig. 1 C). However, with more
extensive deglycosylation a reduction in virus binding was
achieved, consistent with previous findings (Cao et al.,
1998). Further, treatment of 
 
 
 
-DG with neuraminidase
(Fig. 1 D) and competition with soluble sialic acid, treat-
ments that markedly reduced laminin–
 
 
 
-DG binding in
some studies (Yamada et al., 1996), had no effect on the vi-
rus–
 
 
 
-DG interaction. These findings indicate that the
binding of LCMV to 
 
 
 
-DG differs notably from the bind-
ing of 
 
 
 
-DG to laminin, agrin, or perlecan.
 
Amino acids 169–408 of 
 
 
 
-DG contain an essential 
virus binding site
 
Based on previous studies that suggest a modular structure
for 
 
 
 
-DG (Ibraghimov-Beskrovnaya et al., 1992; Brancaccio
et al., 1997), we made the following deletion mutants: DGI
(
 
 
 
H30-A168), DGD (
 
 
 
A182-H315), and DGE (
 
 
 
H30-
A316), with deletions within the NH
 
2
 
-terminal domain of
 
 
 
-DG, DGF (
 
 
 
T317-P408) and DGG (
 
 
 
G409-S485),
with deletions in the central mucin-related domain, and
DGH (
 
 
 
H30-S485), lacking the NH
 
2
 
-terminal and the
mucin-related domain. The 
 
 
 
-DG deletion mutants were
inserted into replication-deficient adenoviral (AdV) vectors.
For the characterization of the recombinant 
 
 
 
-DG variants,
DG
 
 
 
/
 
 
 
 mouse embryonic stem (ES) cells were infected with
the AdV vectors containing the 
 
 
 
-DG deletion mutants and
wild-type DG, resulting in 50–60% of the cells expressed
heterologous protein. The cells were solubilized 48 h after
transfection, and total protein was isolated and probed for
 
 
 
-DG by immunoblotting. All 
 
 
 
-DG deletion mutants
were expressed at comparable levels as assessed by detection
of 
 
 
 
-DG (Fig. 2 B). Clearly present were high levels of the
 
 
 
-DG parts of DGE and DGH that contained an NH
 
2
 
-ter-
minal hemagglutinin (HA) epitope (Fig. 2 D). The presence
of mucin-type glycans on the 
 
 
 
-DG parts was tested by
binding to the lectin jacalin. DG
 
 
 
/
 
  
 
cells were infected with
Figure 2. Expression of  -DG deletion 
mutants in DG
 /  ES cells. (A) Schematic 
representation of the  -DG deletion 
mutants: the putative NH2-terminal 
subdomains, amino acids 30–160 and 
181–316 (white), the mucin-related 
central domain 317–485 (black), and 
the COOH-terminal globular domain 
486–653 (grey) of  -DG are indicated. 
Amino acids 653–895 represent  -DG 
with the transmembrane domain (dark 
box). HA epitopes at the NH2 termini of 
DGE and DGH are indicated. Expression 
of the  -DG deletion mutants: DG
 /  ES 
cells were infected with AdV vectors 
containing the  -DG deletion mutants, 
wild-type DG, or green fluorescent 
protein ( ). 48 h after infection, total 
protein was isolated, separated by SDS-
PAGE, and transferred to nitrocellulose. 
The blots were probed with anti– -DG (B) and anti-HA (D) antibodies using ECL for detection. For isolation of jacalin-binding glycoproteins, cells 
were lysed subjected to jacalin affinity chromatography. Jacalin-bound glycoproteins were probed for  -DG (C) and HA (E) as described above.
Figure 3. Cell surface expression of  -DG deletion mutants in 
DG
 /  ES cells. DG
 /  ES cells were infected with AdV vectors 
containing the  -DG deletion mutants, wild-type DG, or green 
fluorescent protein ( ). 40 h after infection, cell surface protein 
was labeled with biotin-X–NHS and the surface-labeled cells subse-
quently lysed. 80% of the lysate were subjected to affinity precipitation 
with streptavidin-agarose. From the residual 20% of lysate, total 
protein was isolated. Streptavidin-bound proteins (A and B) and 
total protein (C and D) were analyzed by Western-blot using anti–
 -DG antibody (A and C) and anti– -tubulin antibody (B and D), 
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AdV vectors, subsequently solubilized and subjected to jaca-
lin affinity chromatography. Western blot analysis showed
that all  -DG variants except DGH bound efficiently to ja-
calin (Fig. 2, C and E), indicating the presence of the ex-
pected mucin-related structures. This modification and the
coprecipitation with  -DG suggested correct processing of
the recombinant proteins. For the detection of cell surface
expression of the DG variants, a cell surface biotinylation as-
say was used (Fig. 3). 48 h after infection with AdV vectors
containing the different DG variants, DG
 /  cells were
treated with a membrane-impermeable biotinylation re-
agent. Biotin-labeled proteins were recovered by incubating
total cell lysates with streptavidin-agarose. Western blot
analysis revealed comparable biotin labeling of  -DG for all
DG variants (Fig. 3, A and C). The validity of this approach
was verified by showing that only insignificant biotin-label-
ing was observed with the intracellular protein  -tubulin
(Fig. 3, B and D). Given the observed coprecipitation of
 - and  -DG (Fig. 2 C), the efficient cell surface labeling of
 -DG for DGD, E, F, G, I and the wild-type indicates the
expression of comparable amounts of  / -complexes at the
cell surface for these DG variants.
For the analysis of virus binding, jacalin-bound glycopro-
teins were subjected to VOPBA with LCMV clone-13 (Fig.
4 A). Strong binding of LCMV clone-13 to DGI, DGG,
and wild-type DG but not to DGD, DGE, or DGF indi-
cated that the sequence 169–408 of DG contained an essen-
tial binding site(s) for LCMV.
To test the  -DG deletion mutants for reconstitution of
susceptibility to virus infection in nonpermissive cells, we
infected DG
 /  ES cells with the AdV vectors carrying the
 -DG deletion mutants and wild-type DG. Within 48 h af-
ter AdV-mediated gene transfer, cells were infected with LCMV
clone-13. 24 h later, LCMV infection of cells was assessed
by immunofluorescence staining for LCMV-NP. As in
VOPBA (Fig. 4 A), expression of the mutants DGI, DGG,
and wild-type DG but not DGD, DGE, and DGF or DGH
made these cells susceptible to LCMV infection (Fig. 4 B).
Next, we produced soluble  -DG fragments as transcrip-
tional fusion proteins with the heavy chain constant region
of human IgG1 (IgG1 Fc) containing the  -DG sequences
30–181 (DGFc1), 30–316 (DGFc2), 30–408 (DGFc3), 30–
485 (DGFc4), and full-length  -DG 30–653 (DGFc5) (Fig.
5 A).  -DG–Fc fusion proteins were expressed in HEK293T
cells and purified by protein A affinity chromatography. The
molecular masses of the recombinant  -DG–Fc fusion pro-
teins were in agreement with the expected values, and exten-
sive dimerization of the  -DG–Fc fusion proteins was ob-
served under nonreducing conditions. Equal amounts of the
purified proteins DGFc1 through 5 were analyzed by immu-
noblotting using a polyclonal anti–human IgGFc antibody
(Fig. 5 B). VOPBA with LCMV clone-13 revealed virus
binding to DGFc3 through 5 but not to the smaller frag-
ments DGFc1 and DGFc2 (Fig. 5 C). To test virus binding
to the  -DG–Fc fusion proteins under nondenaturing con-
ditions, a dot-VOPBA was performed. Despite comparable
amounts of protein immobilized, as assessed by detection of
human IgG1 Fc, only DGFc3 and DGFc4 but not DGFc1
or DGFc2 exhibited virus binding (Fig. 5 D). These results
combined with those from deletion mutagenesis suggest that
amino acids 169–408 contain structures necessary and suffi-
cient for the LCMV receptor function of  -DG.
Figure 4. Binding of LCMV clone-13 to  -DG deletion mutants 
and reconstitution of susceptibility to virus infection in DG
 /  cells 
using wild-type and deletion mutants of  -DG. (A) Binding of 
LCMV clone-13 to wild-type and deletion mutants of  -DG. Jacalin-
bound glycoproteins (Fig. 2) were subjected to VOPBA with 10
7 
PFU/ml of LCMV clone-13. Bound virus was detected as described 
in the legend to Fig. 1. Molecular masses are indicated. (B) Recon-
stitution of infectivity in DG
 /  ES cells by wild-type and deletion 
mutants of  -DG: DG
 /  ES cells were infected with AdV vectors con-
taining wild-type and deletion mutants of  -DG or a  -galactosidase 
reporter gene (LacZ) at an MOI of 10. At 48 h after AdV-mediated 
gene transfer, cells were infected with LCMV clone-13 (MOI   10). 
Infection levels were assessed 24 h later for the presence of LCMV-
NP by using an anti–LCMV-NP monoclonal antibody and a FITC-
labeled secondary antibody. For each mutant, 100 cells were 
analyzed and green fluorescing cells scored as positive (n   4, 
  SD). These data are representative of triplicate experiments.
Figure 5. Virus binding to  -DG–Fc fusion proteins. (A) Schematic 
representation of the soluble  -DG fragments fused to human 
IgGFc: the putative domains of  -DG are depicted as in Fig. 1, 
and human IgG1Fc is indicated. (B) Detection of Fc: equal amounts 
of purified  -DG–Fc fusion proteins DGFc1 through 5 were 
subjected to SDS-PAGE under nonreducing conditions, blotted to 
nitrocellulose, and probed with a polyclonal antibody to human 
IgGFc. (C) Binding of virus in VOPBA: membranes were incubated 
with 10
7 PFU of LCMV clone-13/ml. Bound virus was detected as 
described in the legend to Fig. 1. Molecular masses are indicated. 
(D) Dot-VOPBA: equal amounts of purified DGFc1 through 4 were 
immobilized on nitrocellulose. Bound protein was detected with a 
polyclonal antibody to human IgGFc (anti-Fc) and ECL. Binding to 
LCMV clone-13 (LCMV) was tested by overlay with 10
7 PFU of 
LCMV clone-13/ml with subsequent detection of virus as described 
in the legend to Fig. 1.Interaction of LCMV with its cellular receptor | Kunz et al. 305
The binding sites for LCMV and laminin-1 on
 -DG overlap
Based on their ubiquitous expression, high binding affinity
to  -DG and large size ECM proteins may interfere with vi-
rus binding to  -DG. To test the possibility that laminin is
one such competitor, we used immobilized  -DG preincu-
bated with increasing amounts of soluble mouse laminin-1
in the presence of divalent cations to form laminin– -DG
complexes. The complexes were incubated with either
LCMV clone-13 that binds  -DG with high affinity or the
low affinity binder LCMV ARM53b. LCMV clone-13 dif-
fers from ARM53b by only a single amino acid exchange at
position 260 of GP1, leucine in clone-13, and phenylalanine
in ARM53b (Salvato et al., 1988). However, LCMV
ARM53b binds at 2.5 logs less affinity to  -DG than does
clone-13 (Sevilla et al., 2000). Laminin-1 blocked binding
of LCMV clone-13 in a dose-dependent manner with a
maximal reduction of 80% with 100  g/ml laminin-1 (Fig.
6 A). In contrast, binding of the low affinity binder, LCMV
ARM53b, was blocked completely by preincubation of
 -DG with laminin-1 (Fig. 5 C). As expected, the laminin-1
concentration that blocked 50% (IC50) of LCMV clone-13
binding was significantly higher that than for ARM53b.
Next, we tested the ability of soluble laminin-1 to displace
LCMV clone-13 or ARM53b from  -DG. We preincu-
bated LCMV clone-13 or ARM53b with immobilized
 -DG to allow the formation of virus receptor complexes.
These complexes were then subjected to displacement by
adding increasing amounts of soluble laminin-1. Although
no significant displacement of prebound LCMV clone-13
was observed with 100  g/ml laminin-1 (Fig. 5 B), pre-
bound ARM53b was displaced easily and efficiently by lami-
nin-1 (Fig. 5 D), indicating that the high affinity binding
variant clone-13 but not its low affinity counterpart com-
peted successfully with laminin-1 for receptor binding.
Laminin clusters at the cell surface reduce
 -DG–mediated infection of LCMV ARM53b but not 
LCMV clone-13
In the light of the competition between LCMV and lami-
nin-1 found, we questioned whether  -DG–associated lami-
nin-1 clusters at the surface of ES cells may interfere with vi-
rus infection. Since ES cells express little if any laminin-1,
the formation of laminin-1 clusters can be induced in both
DG
 /  and DG
 /  but not in DG
 /  ES cells by addition
of purified soluble laminin-1 (Henry and Campbell, 1998).
We cultivated DG
 /  and DG
 /  ES cells either on fi-
bronectin, a substratum that does not involve  -DG for cell
adhesion, or on laminin-1. Regardless of substrate, DG
 / 
ES cells were infected efficiently with LCMV ARM53b and
clone-13, indicating the presence of sufficient amounts of
 -DG at the apical surface to mediate viral entry (Fig. 7 A).
As demonstrated previously (Henry and Campbell, 1998;
Fig. 6), the addition of soluble laminin-1 produced laminin-1
clusters at the surfaces of DG
 /  but not DG
 /  ES cells.
Figure 6. Competition between LCMV and laminin-1 for  -DG 
binding. Blocking of LCMV– -DG binding by soluble laminin-1. 
 -DG from MC57 cells was immobilized on nitrocellulose and 
preincubated with 0, 25, or 100  g/ml soluble mouse laminin-1 in 
the presence of Ca
2  and Mg
2 . 10
7 PFU/ml of LCMV clone-13 (A) 
and 5   10
8 PFU/ml of LCMV ARM53b (C) were applied subse-
quently in the presence of 0, 25, or 100  g/ml laminin-1 and bound 
virus detected as described in the legend to Fig. 1. The ability of sol-
uble laminin-1 to displace bound LCMV clone-13 (B) or ARM53b 
(D) is shown. Immobilized  -DG was incubated with 10
7 PFU/ml of 
LCMV clone-13 (B) and 5   10
8 PFU/ml of ARM53b (D) for 16 h. 
Blots were rinsed, and soluble laminin-1 (0, 25, and 100  g/ml) was 
added in the presence of Ca
2  and Mg
2  for 6 h at room tempera-
ture. Bound virus was detected as described in the legend to Fig. 1.
Figure 7. Blocking of LCMV ARM53b infection of ES cells with 
soluble laminin-1. (A) Infection of ES cells cultivated on fibronectin 
(Fn) and laminin-1 (Ln) substrates is mediated by  -DG. DG
 /  ES 
cells (black bars) and DG
 /  ES cells (white bars) were cultivated on 
Fn or Ln for 20 h before infection with LCMV clone-13 (cl13) and 
ARM53b (ARM) using an MOI of 1. After 16 h, infection levels were 
assessed by staining with a LCMV-NP–specific monoclonal anti-
body. The sequences of the NPs of LCMV ARM53b and clone-13 are 
identical and therefore recognized equivalently by this antibody 
(Salvato et al., 1988). Triplicate samples were counted (500 cells each 
for DG
 /  ES and 200 cells each for DG
 /  cells; n   3,   SD). (B) 
Blocking of LCMV infection of ES cells with soluble laminin-1. DG
 /  
ES cells were cultivated on fibronectin in absence of laminin-1(Fn/0) or 
on laminin in the absence (Ln/0) or in the presence of laminin-1 at 5 
(Ln/5), 12.5 (Ln/12.5), or 50 (Ln/50)  g/ml soluble laminin-1. 24 h 
after the addition of laminin-1, cells were infected with LCMV 
ARM53b (black bars) or clone-13 (white bars) at an MOI of 1 for
16 h. Infection levels were assessed by detecting LCMV-NP. In 
ARM53b-infected specimens, 500 cells were examined per sample; 
in clone-13–infected specimens, 200 cells were examined per 
sample. LCMV-NP–positive cells were scored (n   4,   SD).306 The Journal of Cell Biology | Volume 155, Number 2, 2001
These laminin clusters significantly reduced subsequent in-
fection with LCMV ARM53b but not clone-13 (Fig. 7 B).
Since earlier studies revealed a strikingly different tropism
between LCMV ARM53b and clone-13 in spleen (Borrow
et al., 1995; Sevilla et al., 2000), we compared the expres-
sion of laminin with the expression of the DC marker
CD11c and the infection pattern of ARM53b and clone-13
in this tissue. Immunohistochemical analysis revealed in-
tense laminin expression in the marginal zone at the periph-
ery of the white pulp and surrounding blood vessels (Fig. 8,
a, b, and c) with comparatively minimal staining in the sur-
rounding red pulp. CD11c
  cell clusters were detected
mainly in these laminin-rich areas as illustrated by the exten-
sive overlap between laminin and CD11c staining (Fig. 8 a).
Concurrently, the anatomic distribution of ARM53b and
clone-13 was examined 3 d after infection with 2   10
6
plaque-forming units (pfu) of virus (i.v.) using a digoxige-
nin-labeled probe to LCMV-NP and in situ hybridization
(Fig. 8, e and f) and compared with the localization of lami-
nin (Fig. 8, b and c). Consistent with previous studies (Bor-
row et al., 1995; Fig. 4), LCMV clone-13 localized predom-
inantly to cells in the marginal zone and white pulp (Fig. 8
e), whereas ARM53b localized primarily to cells in the red
pulp (Fig. 8 f). Infection of cells in the marginal zone of the
white pulp with clone-13 colocalized with the expression of
laminin and CD11c. In contrast, there was a disassociation
between infection with ARM53b, which was limited to the
surrounding red pulp with the expression of laminin.
Discussion
Here, we report three novel findings regarding the binding
of LCMV to its cellular receptor  -DG. First, the viral GP
ligand–receptor interaction depends on protein–protein
contacts rather than a lectin-type binding. This finding dis-
tinguishes the different requirements for LCMV from the
ECM molecule laminin binding to  -DG. Second, we map
the site on  -DG to which LCMV binds, showing it com-
prises the COOH-terminal part of the NH2-terminal globu-
lar domain and the NH2-terminal part of the mucin-related
central domain of  -DG. This finding indicates that a piece
of the  -DG receptor is used both by the virus and the
ECM molecule laminin-1. Third, we document competi-
tion between two LCM viruses with ECM molecules like
laminin for  -DG. We show that receptor binding affinity
between viruses for  -DG vary with one set (clone-13) are
able to displace laminin, whereas the other, ARM53b, can
not. The ability to displace laminin is likely a crucial deter-
minant for tissue tropism and subsequent disease caused by
different strains or variants of LCMV.
Biochemical characterization suggests protein–protein 
contacts rather than a lectin-type binding in the 
LCMV– -DG interaction
Considerable evidence suggests that  -DG ECM protein in-
teractions require  -DG–derived carbohydrate structures.
Further, the absolute dependence of  -DG ECM protein in-
teractions on divalent cations, the extreme sensitivity to
chelating agents, enhanced salt concentration, and in some
cases low concentration of heparin (Ervasti and Campbell,
1993; Pall et al., 1996, Andac et al., 1999), all coincide with
the recently solved structure of the  -DG binding sites on
laminin-2 (Hohenester et al., 1999). In contrast, our results
indicate that LCMV– -DG binding is independent of diva-
lent cations and insensitive to chelating agents and heparin.
Extensive neuraminidase treatment, oxidation by low con-
centrations of sodium periodate, and competition with solu-
ble sialic acid, which can reduce the laminin-1– -DG inter-
action (Yamada et al., 1996; Rambukkana et al., 1998), had
no effect on virus binding. Our data agree with previous
studies demonstrating LCMV binding to cells lacking N-
and O-linked sugars after treatment with N- and O-glyca-
nase or virus binding to cells incubated overnight with tuni-
camycin, which inhibits N-linked glycosylation (Borrow
and Oldstone, 1992). Here, we noted that only extensive de-
glycosylation of  -DG reduced virus binding, likely reflect-
ing changes in the overall conformation of the protein rather
than a direct involvement of carbohydrates. Further, the
dramatic changes in virus binding by the single point mu-
tations F260L (ARH53b/clone-13) and S153F (WE54/
WE22) in the LCMV-GP1 (Sevilla et al., 2000) suggest that
Figure 8. Expression pattern of laminin and CD11c and anatomic 
localization of viral nucleic acids of LCMV ARM53b and clone-13 
in the spleen. Detection of laminin and CD11c in whole spleen 
sections. (a) Laminin was detected with a rabbit anti–mouse 
laminin-1 antibody and a FITC-labeled secondary antibody (green). 
CD11c was detected with a hamster anti-CD11c antibody and a 
rhodamine-X–conjugated secondary antibody (red). Overlapping 
fluorescence appears in yellow, since a rhodamine-X/FITC double 
filter device was used. Localization of laminin in the marginal zone 
of the white pulp. (b) Laminin was stained with rabbit anti–laminin-1 
antibody using an HRP-conjugated secondary antibody and DAB as 
a chromophore. Sections were counter stained with hematoxylin 
and eosin. Laminin staining of a single white pulp area. (c and d) 
Laminin was detected with a rabbit anti–laminin-1 antibody and a 
Texas red–conjugated secondary antibody (c). Secondary antibody 
is shown only in d. Detection of viral nucleic acids of LCMV clone-13 
(e) and ARM53b (f) within the spleen 3 d after infection. Spleen 
sections from mice infected 3 d before with 2   10
6 pfu (i.v.) clone-13 
(e), ARM53b (f), or mock infection (g) were examined by in situ 
hybridization using a digoxigenin-labeled riboprobe specific for 
LCMV-NP. MZ, marginal zone; RP, red pulp; WP, white pulp. 
Bars: (a) 200  m; (b–g) 50  m.Interaction of LCMV with its cellular receptor | Kunz et al. 307
protein–protein interactions rather than a carbohydrate-
mediated lectin-type binding play a crucial role in the for-
mation of viral GP1– -DG complexes. However, the marked
reduction of virus binding upon deglycosylation denotes an
important function of carbohydrates for the conformational
stability and/or proper folding of the virus binding site. This
indirect role of  -DG–derived glycans is supported by our
finding that structures within the mucin-related domain of
 -DG are necessary for virus binding.
Virus binding involves the COOH-terminal part of the 
NH2-terminal globular domain and the NH2-terminal 
part of the mucin-related central domain of  -DG
Using a combination of deletion mutagenesis and binding
studies with  -DG fragments, we found that structures
formed by amino acids 169–408 of  -DG are necessary and
sufficient for virus binding. Based on its amino acid se-
quence, a modular structure of  -DG has been proposed
(Ibraghimov-Beskrovnaya et al., 1992). Presumably, amino
acids 30–316 of  -DG form an independent folding unit
composed of at least two independent subdomains, that is,
residues 30–180 and residues 181–316 (Brancaccio et al.,
1997). The expression of the DG mutants DGI ( H30-
A168), DGD ( A182-315), and DGE ( H30-A316) as
stable proteins in eukaryotic cells supports this proposed
modular structure. The central region of  -DG (residues
316–485) is related to mucins and contains a great number
of terminally sialylated O-linked sugar chains that exhibit re-
markable tissue-specific differences. Based on these data, the
virus-binding region mapped in this study included the pro-
posed second globular subdomain of the NH2-terminal por-
tion of  -DG and part of the adjacent mucin-related domain.
Our biochemical data dispute a participation of terminal
sialic acids of the mucin-type O-linked sugar chains as pro-
posed by some studies for laminin binding (Yamada et al.,
1996), making a function of mucin-type glycans for the con-
formational stability and/or proper folding of the virus bind-
ing site more probable. However, binding to the polypep-
tide core structure of the mucin-type domain or recognition
of some unknown structures such as specific carbohydrate
entities or chemically modified amino acid side chains by
the virus remains possible.
The binding site of LCMV on  -DG overlaps with the 
one used by laminin-1 and likely other ECM molecules
A striking feature of DG is its complex binding pattern in-
volving a wide variety of proteins. Hence,  -DG at the cell
surface might be covered by ECM molecules and cellular
proteins. Some of these  -DG–associated proteins may en-
hance virus binding, perhaps as cofactors or coreceptors.
Other DG-associated proteins may compete with the virus
for overlapping binding sites on  -DG and thereby block its
function as a viral receptor. Using purified proteins in an in
vitro binding assay, we demonstrated a competition between
laminin-1 and LCMV for  -DG binding. Since laminin-1,
laminin-2, agrin, and perlecan occupy overlapping binding
sites on  -DG (Talts et al., 1999), our data for laminin-1
likely apply to these ECM components. Therefore, the sus-
ceptibility of a specific cell to arenavirus infection in vivo
may depend not only on the expression of  -DG itself but
also on  -DG’s association with host-derived proteins. If so,
binding affinity for  -DG represents a crucial determinant
for the tissue tropism and selection of viruses within a given
host (Borrow et al., 1995; Sevilla et al., 2000).
Competition between virus and ECM molecules for 
 -DG likely underlies the observation that receptor 
binding affinity is a crucial determinant for tissue 
tropism and subsequent pathogenesis of selected 
LCMV strains and variants
Comparative studies in vivo revealed that the closely related
LCMV ARM53b and clone-13 display markedly different
courses of disease. Both viruses cause a persistent infection
upon congenital, neonatal, or in utero infection. However,
infection of adult immunocompetent animals only with
clone-13 but not ARM53b causes a persistent infection
(Ahmed et al., 1984). In contrast to the persistent infection
initiated early in life that is due to thymic deletion of antivi-
ral immune cells, persistent infection of adult animals with
clone-13 is associated with a generalized immunosuppres-
sion (Oldstone et al., 1973; Borrow et al., 1995). These dis-
tinct pathologies of ARM53b and clone-13 are reflected by a
different tissue tropism in spleen. Clone-13 was noted to
replicate preferentially in the white pulp of the spleen and
infect CD11c
  interdigitating DC, whereas in contrast
ARM53b localized primarily to the red pulp of the spleen
with almost complete absence from the white pulp (Borrow
et al., 1995). At the structural level, clone-13 differs from
ARM53b by only two point mutations, K1079Q in the viral
polymerase and F260L in the viral glycoprotein (Salvato et
al., 1988; Salvato et al., 1991). Although both viruses use
 -DG as their cellular receptor (Cao et al., 1998), clone-13
binds to  -DG with much higher affinity than ARM53b
(Sevilla et al., 2000). Recent comprehensive studies of nu-
merous LCMV strains and variants generated in vivo dem-
onstrated that enhanced receptor binding affinity, tropism
to DC, biological consequences of immunosuppression, and
persistent infection all reflect consistently a F260L or F260I
mutation in LCMV-GP1, the component that binds the cel-
lular receptor (Sevilla et al., 2000). The selection of LCMV
variants over time in different lymphoid and other organs
further reveals strong selective pressure for an aliphatic
amino acid in position 260 of the LCMV-GP (Evans et al.,
1994; Sevilla et al., 2000). Since  -DG in the spleen is ex-
pressed preferentially in the professional antigen-presenting
DEC 205
  and CD11c
  DC, the result is selective infection
of these cells that may alter their function and cause immu-
nosuppression (Sevilla et al., 2000).
The present study demonstrates that high affinity binding
LCMV variants like clone-13 compete successfully with
laminin-1 for  -DG binding and that  -DG–associated
laminin-1 clusters at the cell surface did not affect clone-13
infection significantly. In contrast, the low affinity binding
variant ARM53b was displaced from its receptor binding site
by soluble laminin-1, and laminin-1 clusters at the cell sur-
face reduced ARM53b infection. Based on their overlapping
binding sites on  -DG (Talts et al., 1999), ECM compo-
nents like laminin-1, laminin-2, perlecan, and agrin may pro-308 The Journal of Cell Biology | Volume 155, Number 2, 2001
vide a barrier for infection of cells by low affinity binding
LCMV variants and influence tissue tropism and, as a conse-
quence, the outcome of disease. Especially in organs with low
concentrations of  -DG, such as the spleen (Durbeej et al.,
1998),  -DG–associated ECM may be an important deter-
minant for the anatomic distribution of LCMV variants with
different receptor binding affinities. Therefore, we compared
the expression pattern of laminin in the spleen with the dis-
tribution of ARM53b and clone-13. In line with previous
studies (van den Berg et al., 1993), we found particularly
strong laminin expression in the marginal zone at the periph-
ery of the white pulp. Since laminin expression in the
marginal zone extensively colocalized with the expression
CD11c, a marker for  -DG
  DC (Sevilla et al., 2000), this
area likely represents a major site of infection of these cells by
LCMV. Accordingly, 2–3 d after i.v. inoculation, cells in the
marginal zone were infected heavily with clone-13, whereas
ARM53b infected cells were virtually absent from this region
but localized primarily to the surrounding red pulp. The
overlap between laminin expression and infection with clone-
13 suggests that this virus efficiently infects cells surrounded
by laminin. By contrast, the lack of association between lami-
nin expression and the distribution of ARM53b suggests, in
agreement with our in vitro studies, that laminin interferes
with ARM53b infection. We speculate that high receptor
binding affinity may enable variants like clone-13 to displace
 -DG–associated ECM molecules from the surface of
CD11c
  DCs in the marginal zone, resulting in infection of
these cells. Our earlier studies showed that  80% of such
DCs are infected with clone-13 (Sevilla et al., 2000). Prelim-
inary studies showed that infected DC subsequently migrate
into the white pulp and disseminate the virus into the T cell
area. Low affinity binders like ARM53b that are unable to
displace   -DG–associated ECM components infect small
numbers of CD11c
  DC in the marginal zone with  10%
of these cells infected by this virus (Sevilla et al., 2000). Be-
cause of the lower binding affinity to  -DG, resulting in less
efficient infection of DCs, ARM53b may be excluded from
the white pulp and is found in the red pulp. The more effi-
cient infection of cells in the red pulp by ARM53b when
compared with clone-13 may reflect the ability of ARM53b
to use alternative cellular receptors for infection, a possibility
that is supported by recent data from our laboratory (Smelt et
al., 2001). In addition to spleen, expression of laminin is
found in other lymphoid tissues that may represent sites of
LCMV infection of DCs (van den Berg et al., 1993; Jaspars
et al., 1995; Nilsson et al., 1998). However, the detailed dis-
tribution of laminin isoforms in these tissues is currently
poorly understood. Since recent studies suggest a more re-
stricted expression pattern of laminin-1 than previously
thought (Falk et al., 1999), our staining with an antibody to
laminin-1 may be due to recognition of laminin  1 and/or
 1 chains of other laminin isoforms that we are currently
evaluating.
A similar in vivo selection of LCMV variants with high af-
finity for  -DG is also observed in nonlymphoid organs,
such as kidney, liver, and lung (Evans et al., 1994), suggest-
ing that the selection of variants with high receptor binding
affinity is a more general phenomenon and may represent a
selective advantage during the natural infectious process.
Materials and methods
Animals
Female C57Bl/6 mice were obtained from the rodent breeding colony at
The Scripps Research Institute and were bred and maintained under spe-
cific pathogen-free conditions.
Proteins and antibodies
 -DG was purified as described (Ervasti and Campbell, 1991). Mouse EHS
laminin-1 was from GIBCO-BRL. Streptavidin coupled to agarose was from
Sigma-Aldrich. Monoclonal antibodies 1-1-3 (anti–LCMV-NP), WE36.1,
and WE 33.1 (anti–LCMV-GP1 and GP2) have been described (Buchmeier
et al., 1981), as has polyclonal rabbit antibody AP83 against  -DG (Henry
and Campbell, 1998). Polyclonal rabbit anti–mouse EHS laminin antibody
and mouse monoclonal antibody DM1A anti– -tubulin were purchased
from Sigma-Aldrich, rabbit anti–influenza HA epitope antibody Y11 from
Santa Cruz Biotechnology, Inc., and hamster anti-CD11c from Serotec.
FITC-conjugated goat anti–mouse IgG, FITC-conjugated goat anti–rabbit
IgG, rhodamine–X-labeled anti–Armenian hamster IgG, and rhodamine-X–
conjugated anti–rabbit IgG were from Jackson ImmunoResearch Laborato-
ries. HRP-conjugated antibody against human IgGFc was purchased from
Sigma-Aldrich, and HRP-conjugated antibody against mouse and rabbit
IgG were from Pierce Chemical Co.
Construction of the DG deletion mutants and  -DG–Fc 
fusion proteins
For the construction of the DG deletion mutants, rabbit DG cDNA frag-
ments were amplified by PCR and inserted into the eukaryotic expression
vector DGpDisplay, resulting in the following deletion mutants: DGI
( H30-R168), DGD ( C182-H315), DGE ( H30-A316), DGF ( T317-
P408), DGG ( G409-S485), and DGH ( H30-S485).
For the construction of the  -DG–Fc fusion proteins, the following
 -DG sequences were inserted into the expression construct IgG1Fcp-
cDNA3 (Chen et al., 1996): DGFc1, amino acids 30–181; DGFc2, amino
acids 30–316; DGFc3, amino acids 30–408; DGFc4, amino acids 30–485;
and full-length  -DG–Fc, DGFc5, amino acids 30–653. For detailed clon-
ing strategies see Online supplemental material.
Production and purification of  -DG–Fc fusion proteins
HEK293T cells were transiently transfected using calcium phosphate. 60 h
after transfection, cells were lysed in 1% (wt/vol) Triton X-100, 0.1% (wt/
vol) SDS, 5 mM EDTA, 1 mM PMSF in PBS with protease inhibitor com-
plete (Roche) and lysates cleared by centrifugation (10 min, 14,000 rpm,
4 C). 20  l/ml protein A–Sepharose 4B (Amersham Pharmacia Biotech)
was added and incubated in the cold for 12 h. The matrix was washed
twice with a 20 vol of lysis buffer, three times with a 20 vol of PBS, and
then eluted with a fivefold volume 0.1 M glycine/HCl, pH 2.80. The eluate
was neutralized immediately with 1 M Tris/HCl, pH 8.0, and dialyzed
against PBS.
Generation of replication-deficient recombinant AdV vectors
For construction of the AdV shuttle plasmids, the cDNA fragments encod-
ing the DG deletion mutants and wild-type DG were excised from the
pDisplay-based expression constructs by HindIII and NotI and inserted
into the shuttle plasmid pAdV/RSV. pAdV/RSV contains an Rous sarcoma
virus long terminal repeat-driven expression cassette with a bovine growth
hormone polyadenylation signal inserted between base pairs 455 and
3328 of the E1 region of human AdV5. Replication-deficient AdV vectors
were generated by in vivo recombination of the AdV genomic plasmid
pBHG10 with the pAdV/RSV shuttle plasmids in HEK293 cells as de-
scribed (Bett et al., 1994). Twofold plaque-purified isolates were amplified,
purified by CsCl gradient centrifugation, and screened for protein expres-
sion by Western blot analysis.
Virus strains, virus purification, and virus quantification
LCMV Armstrong ARM53b is a triple plaque-purified isolate of ARM CA
1371 (Dutko and Oldstone, 1983). LCMV clone-13 is a plaque-purified
variant of ARM53b derived from spleen cells of an adult BALB/WEHI
mouse infected persistently since birth with ARM53b (Ahmed et al., 1984).
Seed stocks of all viruses were prepared by growth in BHK-21 cells. Puri-
fied virus stocks were produced and their titers determined as described
(Dutko and Oldstone, 1983).
ES cells
DG
 /  and DG
 /  mouse ES cells (Henry and Campbell, 1998) were main-
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LCMV infection by AdV-mediated gene transfer was performed as de-
scribed in Cao et al. (1998). For blocking LCMV infection with soluble
laminin-1, DG
 /  ES cells were plated in 24-well plates coated with 5  g/
cm
2 laminin-1 or fibronectin in a density of 10
4 cells/well. After overnight
incubation, the culture medium was replaced with fresh medium contain-
ing 0, 5, 12.5, and 50  g/ml laminin-1. 24 h later, LCMV was added at a
multiplicity of infection (MOI) of 1 and incubated for 1 h at 37 C. The viral
particles were removed and fresh medium containing 0, 5, 12.5, and 50
 g/ml laminin-1 added. After 16 h, infected cells were determined by im-
munofluorescence staining for LCMV-NP as described (Smelt et al., 2001).
Biotinylation of cell surface proteins
For cell surface biotinylation assay, DG
 /  mouse ES cells (4   10
5 cells/
well) were plated in gelatin-pretreated 6-well plates. After a 24-h incuba-
tion, AdV vectors were applied in an MOI of 10 and cells incubated for
40 h before cell surface labeling. Surface-specific biotinylation and isola-
tion of biotinylated proteins was accomplished as described in Gonzalez-
Dunia et al. (1997).
Immunoblotting
For isolation of total protein, cells were lysed in 1% (wt/vol) Triton X-100,
1% (wt/vol) CHAPS, 0.1% (wt/vol) SDS, 5 mM EDTA, 1mM PMSF, 1 mM
iodoacetamide, 100 mM NaCl, 50 mM Tris/HCl, pH 7.5, and proteins pre-
cipitated (Wessel and Flugge, 1984). For isolation of jacalin-binding glyco-
proteins, cells were washed three times with PBS and solubilized in 1%
(wt/vol) NP-40, 50 mM Hepes, 200 mM NaCl, 1.2 mM EDTA, 5 mM
MgCl2, 5 mM CaCl2, pH 7.5, containing protease inhibitor cocktail com-
plete and 1 mM PMSF. Lysates were cleared by centrifugation at 14,000
rpm for 10 min at 4 C and incubated with 20  l/ml jacalin conjugated to
agarose (Vector Laboratories) for 12 h at 6 C. The lectin matrix was
washed twice with 20 vol of solubilization buffer and three times with 50
mM Hepes, 200 mM NaCl, 0.05% (wt/vol) NP-40, 1.2 mM EDTA, 5 mM
MgCl2, and 5 mM CaCl2, pH 7.5. Jacalin-bound proteins were eluted by
boiling in SDS-PAGE sample buffer, separated by gel electrophoresis, and
transferred to nitrocellulose. After blocking in 5% (wt/vol) skim milk/PBS,
membranes were incubated with the primary antibody (AP83 anti– -DG
in a dilution of 1:500; Y11 anti-HA 1:5,000; HRP-conjugated anti–human
IgG1Fc, 1:20,000; DM1A anti– -tubulin 1:1,000) in 2% (wt/vol) skim
milk/PBS for 12 h at 6 C. HRP-conjugated secondary antibodies goat anti–
rabbit IgG and goat anti–mouse IgG (Pierce Chemical Co.) were applied in
a dilution of 1:5,000 for 1 h at room temperature. Blots were developed
using Super Signal ECL substrate (Pierce Chemical Co.) and signals re-
corded on autoradiographic film (Eastman Kodak, Co.).
VOPBA, biochemical characterization of the LCMV– -DG 
interaction, and laminin overlay assay
VOPBA was performed as described (Cao et al., 1998). The dependence of
virus– -DG binding on divalent cations was tested by including 1 mM
CaCl2, 1 mM MgCl2, 10 mM EDTA, or 10 mM EGTA in the virus overlay
solution (10
7 pfu/ml LCMV in VOB: 1% (wt/vol) BSA, 20 mM Hepes, 150
mM NaCl, pH 7.5). For heparin-blocking experiments, 10
7 pfu/ml LCMV
were preincubated with 0, 25, and 100 mg/ml heparin (grade I-A from por-
cine intestinal mucosa [Sigma-Aldrich]) in VOB containing 5 mM CaCl2
and 5 mM MgCl2 on ice for 45 min. Sodium periodate treatment was per-
formed on PVDF membranes by incubation with 0. 0.1, 1, and 10 mM so-
dium periodate in 0.1 M NaOAc, pH 5.5, for 20 min at room tempera-
ture. For neuraminidase treatment, blots were incubated with 1 U/ml
neuraminidase from arthrobacter urefaciens (Calbiochem) in 0.5 M
NaOAc, pH 5.5, 1% (wt/vol) NP-40, 0.1% (wt/vol) SDS for 24 h at 37 C.
Blocking of virus binding by soluble sialic acid was tested by preincuba-
tion of LCMV clone-13 (10
7 pfu/ml) in VOB containing 1 mM CaCl2, 1 mM
MgCl2, and 0, 10, and 100 mM sialic acid (Sigma-Aldrich). For blocking of
virus binding by laminin-1,  -DG blots were incubated with 0, 25, and
100  g/ml laminin-1 in laminin overlay buffer (LOB: VOB containing 1
mM CaCl2, 1 mM MgCl2) for 4 h at room temperature. 10
7 pfu/ml LCMV
clone-13 or 5   10
8 pfu/ml LCMV ARM53b in LOB containing 0, 25, or
100  g/ml laminin-1 were added to the blots and incubated for 12 h at
6 C. For laminin-1 displacement experiments, blots with immobilized
 -DG were incubated with 10
7 pfu/ml LCMV clone-13 or 5   10
8 pfu/ml
LCMV ARM53b in LOB for 12 h at 6 C. For displacement of bound virus,
0, 25, or 100  g/ml laminin-1 in LOB were added and incubated at room
temperature for 6 h.
Laminin overlay assay was performed as described (Durbeej and Camp-
bell, 1999) in the presence of divalent cations or in the presence of 10 mM
EDTA or 10 mM EGTA. For blocking with heparin, laminin-1 was preincu-
bated for 1 h on ice with 0.25 and 100 mg/ml heparin in LOB.
Detection of LCMV-NP by in situ hybridization
Generation of riboprobes to LCMV-NP and in situ hybridization are de-
scribed elsewhere (Sevilla et al., 2000). For the present study, C57Bl/6
mice were infected as adults (7–10 wk old) by i.v. inoculation of 2   10
6
pfu of LCMV ARM53b or clone-13. Spleens from three animals for each
experimental group were analyzed by in situ hybridization 3 d after infec-
tion.
Immunohistochemistry
For immunofluorescence, spleens from adult uninfected C57Bl/6 mice
were collected, embedded in Tissue-Tek OCT compound (Miles Diagnos-
tic Division), and frozen on dry ice. 6  m thick sections were cut on a
cryostat, placed onto Fisher Scientific Superfrost Plus microscopic slides,
dried, and fixed in cold ethanol. Rabbit anti–laminin-1 antibody (1:1,000)
and hamster anti-CD11c antibody (1:100) were incubated at room temper-
ature for 1 h. As secondary antibodies, anti–rabbit IgG conjugated to
rhodamine-X or FITC and anti–hamster IgG conjugated to rhodamine-X
were used in a dilution of 1:100. The whole spleen composite shown in
Fig. 8 a was obtained using a ZEISS Axiovert S100 microscope fitted with a
5  objective, an AxioCam digital camera, and an automated stage. Two-
color registered images were captured using 490 and 570 nm excitation.
For image reconstruction, MosaiX function in the KS300 image analysis
software (Kontron) was used. Immunohistochemical staining using DAB as
a chromogen was performed as described (Borrow et al., 1995) using rab-
bit anti–laminin-1 in a dilution of 1:1,000 and HRP-conjugated anti–rabbit
IgG as a secondary antibody. Sections were counter stained with Mayer’s
hematoxylin (Sigma-Aldrich).
Online supplemental material
Supplemental text describes the construction of the DG deletion mutants
and the  -DG–Fc fusion proteins. Fig. S1 shows in situ hybridization to
compare the location of viral nucleic acids within the spleen 3 d after in-
fection with LCMV ARM53b and clone-13, counterstained with hematoxy-
lin and eosin. All online supplemental material available at http://
www.jcb.org/content/vol155/issue2.
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